Matthew R Weir

List of Publications by Citations

Source: https://exaly.com/author-pdf/1830663/matthew-r-weir-publications-by-citations.pdf

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

19,411 474 74 122 h-index g-index citations papers 6.76 22,650 5.6 516 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
474	Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. <i>Archives of Internal Medicine</i> , 2000 , 160, 685-93		544
473	MYH9 is associated with nondiabetic end-stage renal disease in African Americans. <i>Nature Genetics</i> , 2008 , 40, 1185-92	36.3	518
472	The frequency of hyperkalemia and its significance in chronic kidney disease. <i>Archives of Internal Medicine</i> , 2009 , 169, 1156-62		381
471	Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. <i>New England Journal of Medicine</i> , 2015 , 372, 211-21	59.2	376
470	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. <i>Lancet, The</i> , 2010 , 375, 1173-81	40	374
469	Clinical course of polyoma virus nephropathy in 67 renal transplant patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 2145-51	12.7	357
468	Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. <i>Archives of Internal Medicine</i> , 2003 , 163, 1555-65		315
467	Risk for posttransplant Diabetes mellitus with current immunosuppressive medications. <i>American Journal of Kidney Diseases</i> , 1999 , 34, 1-13	7.4	302
466	Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. <i>Circulation</i> , 2001 , 104, 2280	-816.7	274
465	Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 151-61	27.4	260
464	A prospective controlled study of kidney donors: baseline and 6-month follow-up. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 577-86	7.4	258
463	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 434-80	15.1	253
462	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 2221-2232	12.7	241
461	Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. <i>Transplantation</i> , 1999 , 68, 396-402	1.8	241
460	Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 441-51	7.4	236
459	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. <i>Journal of the American Society of</i>	12.7	225
458	Nephrology: JASN, 2007 , 18, 1540-6 Microalbuminuria and cardiovascular disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007 , 2, 581-90	6.9	220

(2013-1999)

457	Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. <i>Human Pathology</i> , 1999 , 30, 970-7	3.7	213
456	Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 2198-205	15.1	208
455	Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. <i>Kidney International</i> , 1998 , 54, 1283-9	9.9	200
454	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. <i>Endocrine Practice</i> , 2016 , 22, 753-62	3.2	186
453	Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1678-89	27.4	185
452	A comparison of recipient renal outcomes with laparoscopic versus open live donor nephrectomy. <i>Transplantation</i> , 1999 , 67, 722-8	1.8	184
451	Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of	16.7	181
450	Transplantation, and National Kidney Foundation. <i>Circulation</i> , 2012 , 126, 617-63 Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1051-6	50 ^{15.1}	179
449	Cardiovascular events during differing hypertension therapies in patients with diabetes. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 77-85	15.1	172
448	Aortic PWV in chronic kidney disease: a CRIC ancillary study. <i>American Journal of Hypertension</i> , 2010 , 23, 282-9	2.3	160
447	Differential effects of calcium antagonist subclasses on markers of nephropathy progression. <i>Kidney International</i> , 2004 , 65, 1991-2002	9.9	156
446	Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2012 , 60, 250-61	7.4	154
445	Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. <i>Kidney International</i> , 2011 , 79, 897-907	9.9	149
444	Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. <i>Kidney International</i> , 2001 , 59, 1567-73	9.9	147
443	Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 531-48	6.9	146
442	Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. <i>Circulation</i> , 2011 , 123, 1763-70	16.7	140
441	Morphological Spectrum of Polyoma Virus Disease in Renal Allografts: Diagnostic Accuracy of Urine Cytology. <i>American Journal of Transplantation</i> , 2001 , 1, 373-381	8.7	136
440	KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 201-13	7 ⋅4	133

439	Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. <i>Clinical Therapeutics</i> , 2007 , 29, 1803-24	3.5	129
438	A novel approach to the treatment of chronic allograft nephropathy. <i>Transplantation</i> , 1997 , 64, 1706-10	01.8	129
437	Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 642	2-52	121
436	Urinary Sodium and Potassium Excretion and CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2016 , 27, 1202-12	12.7	120
435	Hypertension in CKD: Core Curriculum 2019. American Journal of Kidney Diseases, 2019, 74, 120-131	7.4	120
434	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. <i>Kidney International</i> , 2008 , 74, 364-9	9.9	119
433	Current status of kidney and pancreas transplantation in the United States, 1994-2003. <i>American Journal of Transplantation</i> , 2005 , 5, 904-15	8.7	118
432	Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. <i>Hypertension</i> , 1997 , 30, 140-5	8.5	118
431	A prospective controlled study of living kidney donors: three-year follow-up. <i>American Journal of Kidney Diseases</i> , 2015 , 66, 114-24	7.4	112
430	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet, The</i> , 2013 , 381, 537-45	40	109
429	Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. <i>Hypertension</i> , 1998 , 31, 1088-96	8.5	108
428	Assessment and management of hypertension in patients on dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1630-46	12.7	106
427	Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. <i>European Journal of Heart Failure</i> , 2015 , 17, 1057-65	12.3	106
426	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020 , 97, 42-61	9.9	106
425	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018 , 39, 2314-2325	9.5	104
424	Assessment and management of hypertension in transplant patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015 , 26, 1248-60	12.7	103
423	Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010 , 5, 1255-60	6.9	102
422	Insulin resistance, elevated glomerular filtration fraction, and renal injury. <i>Hypertension</i> , 1996 , 28, 127-	3 2 8.5	102

(2014-2003)

421	Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. <i>American Heart Journal</i> , 2003 , 146, 591-604	4.9	100
420	Evaluation of pancreas transplant needle biopsy: reproducibility and revision of histologic grading system. <i>Transplantation</i> , 1997 , 63, 1579-86	1.8	100
419	Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy. <i>Annals of Surgery</i> , 1996 , 224, 440-9; discussion 449-52	7.8	97
418	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019 , 95, 1304-1317	9.9	96
417	Novel RAAS agonists and antagonists: clinical applications and controversies. <i>Nature Reviews Endocrinology</i> , 2015 , 11, 242-52	15.2	94
416	The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. <i>American Heart Journal</i> , 2008 , 155, 823-8	4.9	93
415	Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. <i>Hypertension</i> , 1995 , 26, 124-30	8.5	92
414	Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis. <i>American Journal of Nephrology</i> , 2016 , 43, 229-36	4.6	91
413	Development and validation of GFR-estimating equations using diabetes, transplant and weight. <i>Nephrology Dialysis Transplantation</i> , 2010 , 25, 449-57	4.3	90
412	Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study. <i>Hypertension</i> , 2016 , 67, 387-	.9 <mark>8</mark> 5	89
411	Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. <i>Hepatology</i> , 2014 , 59, 1532-42	11.2	88
410	Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study. <i>Annals of Internal Medicine</i> , 2015 , 162, 258-65	8	87
409	Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). <i>Current Medical Research and Opinion</i> , 2014 , 30, 1759-68	2.5	85
408	An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. <i>American Journal of Nephrology</i> , 2006 , 26, 268-75	4.6	84
407	Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. <i>Journal of the American Society of Hypertension</i> , 2007 , 1, 264-77		78
406	A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. <i>Transplantation</i> , 2016 , 100, 184-93	1.8	76
405	Variability of creatinine measurements in clinical laboratories: results from the CRIC study. <i>American Journal of Nephrology</i> , 2010 , 31, 426-34	4.6	75
404	Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. <i>Journal of Clinical Hypertension</i> , 2014 , 16, 875-82	2.3	74

403	Retransplantation in patients with graft loss caused by polyoma virus nephropathy. <i>Transplantation</i> , 2004 , 77, 131-3	1.8	74
402	Implications of a health lifestyle and medication analysis for improving hypertension control. <i>Archives of Internal Medicine</i> , 2000 , 160, 481-90		74
401	Salt-induced increases in systolic blood pressure affect renal hemodynamics and proteinuria. Hypertension, 1995 , 25, 1339-44	8.5	74
400	Double adult renal allografts: a technique for expansion of the cadaveric kidney donor pool. <i>Surgery</i> , 1996 , 120, 580-3; discussion 583-4	3.6	73
399	Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2874-81		72
398	Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 202-9	2.3	72
397	Angiotensin-converting enzyme inhibitors. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 667-75	2.3	70
396	Increased living donor volunteer rates with a formal recipient family education program. <i>American Journal of Kidney Diseases</i> , 1997 , 29, 739-45	7.4	69
395	Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. <i>American Heart Journal</i> , 1995 , 130, 359-66	4.9	68
394	Pancreas allograft biopsy: safety of percutaneous biopsy-results of a large experience. <i>Transplantation</i> , 2002 , 73, 553-5	1.8	68
393	Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary. <i>American Journal of Kidney Diseases</i> , 2005 , 45, 176-88	7.4	67
392	Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. <i>Kidney International</i> , 2015 , 88, 1427-1433	9.9	66
391	Plant protein intake is associated with fibroblast growth factor 23 and serum bicarbonate levels in patients with chronic kidney disease: the Chronic Renal Insufficiency Cohort study. <i>Journal of Renal Nutrition</i> , 2012 , 22, 379-388.e1	3	66
390	Significance of the Banff borderline biopsy. <i>American Journal of Kidney Diseases</i> , 1996 , 28, 585-8	7.4	65
389	Acute effects of intravenous cyclosporine on blood pressure, renal hemodynamics, and urine prostaglandin production of healthy humans. <i>Transplantation</i> , 1990 , 49, 41-7	1.8	64
388	Association of Pulse Wave Velocity With Chronic Kidney Disease Progression and Mortality: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). <i>Hypertension</i> , 2018 , 71, 1101-1107	8.5	62
387	A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil \(\frac{1}{2} \) hydrochlorothiazide. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 404-12	2.3	62
386	Genotype-based changes in serum uric acid affect blood pressure. <i>Kidney International</i> , 2012 , 81, 502-7	9.9	62

385	Isolated pancreas rejection in combined kidney pancreas tranplantation. <i>Transplantation</i> , 1996 , 61, 974-	7 1.8	61
384	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007 , 16, 13-9	1.7	59
383	Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. <i>Journal of Clinical Hypertension</i> , 2003 , 5, 330-5	2.3	58
382	BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. <i>Transplantation</i> , 2004 , 78, 1069-73	1.8	58
381	Polyomavirus nephropathy in native kidneys of a solitary pancreas transplant recipient. <i>Transplantation</i> , 2002 , 73, 1350-3	1.8	58
380	Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. <i>Journal of the National Medical Association</i> , 2009 , 101, 34-9	2.3	57
379	High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. <i>American Journal of Transplantation</i> , 2020 , 20, 2491-2498	8.7	56
378	Histologic grading of acute allograft rejection in pancreas needle biopsy: correlation to serum enzymes, glycemia, and response to immunosuppressive treatment. <i>Transplantation</i> , 1998 , 66, 1741-5	1.8	55
377	A study of renal outcomes in obese living kidney donors. <i>Transplantation</i> , 2010 , 90, 993-9	1.8	54
376	RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. <i>Current Hypertension Reports</i> , 2003 , 5, 408-17	4.7	54
375	Renal effects of nonselective NSAIDs and coxibs. <i>Cleveland Clinic Journal of Medicine</i> , 2002 , 69 Suppl 1, SI53-8	2.8	54
374	Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. <i>American Journal of Nephrology</i> , 2004 , 24, 379-86	4.6	53
373	Double renal allografts successfully increase utilization of kidneys from older donors within a single organ procurement organization. <i>Transplantation</i> , 1996 , 62, 1581-3	1.8	53
372	Non-GFR Determinants of Low-Molecular-Weight Serum Protein Filtration Markers in CKD. <i>American Journal of Kidney Diseases</i> , 2016 , 68, 892-900	7.4	53
371	Measured GFR does not outperform estimated GFR in predicting CKD-related complications. Journal of the American Society of Nephrology: JASN, 2011 , 22, 1931-7	12.7	52
370	The prognostic value of the eosinophil in acute renal allograft rejection. <i>Transplantation</i> , 1986 , 41, 709-	12 8	52
369	Cardiovascular risk assessment in kidney transplantation. <i>Kidney International</i> , 2015 , 87, 527-34	9.9	50
368	Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. <i>Kidney International Reports</i> , 2016 , 1, 256-268	4.1	50

367	Urine neutrophil gelatinase-associated lipocalin and risk of cardiovascular disease and death in CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 267-74	7.4	49
366	BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 1554-62	12.7	49
365	Drug interactions in transplant patients: what everyone should know. <i>Current Opinion in Nephrology and Hypertension</i> , 2009 , 18, 404-11	3.5	49
364	Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. <i>Hypertension</i> , 2011 , 57, 174-9	8.5	48
363	Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. <i>Circulation: Heart Failure</i> , 2011 , 4, 18-26	7.6	48
362	Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. <i>Archives of Internal Medicine</i> , 2005 , 165, 181-6		48
361	Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. <i>Kidney International</i> , 2019 , 96, 489-504	9.9	47
360	Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. <i>Clinical Therapeutics</i> , 1996 , 18, 411-28	3.5	47
359	Preemptive renal transplantation: why not?. American Journal of Transplantation, 2003, 3, 1336-40	8.7	46
358	Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. <i>Kidney International</i> , 2011 , 80, 288-94	9.9	45
357	The independent association between serum uric acid and graft outcomes after kidney transplantation. <i>Transplantation</i> , 2010 , 89, 573-9	1.8	45
356	Microalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 134-41; quiz 142-3	2.3	45
355	Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020 , 97, 861-876	9.9	44
354	Diuretics and beta-blockers: is there a risk for dyslipidemia?. <i>American Heart Journal</i> , 2000 , 139, 174-83	4.9	44
353	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1379-1390	15.1	43
352	The evolving role of mTOR inhibition in transplantation tolerance. <i>Journal of the American Society of Nephrology: JASN</i> , 2011 , 22, 408-15	12.7	42
351	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021 , 99, 34-47	9.9	42
350	Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. <i>Clinical Transplantation</i> , 2012 , 26, E438-46	3.8	41

(2003-2007)

349	Cigarette smoking and incident chronic kidney disease: a systematic review. <i>American Journal of Nephrology</i> , 2007 , 27, 342-51	4.6	41	
348	Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. <i>American Journal of Hypertension</i> , 2002 , 15, 550-6	2.3	41	
347	Correlation of in vitro CD4+ T helper cell function with clinical graft status in immunosuppressed kidney transplant recipients. <i>Transplantation</i> , 1991 , 52, 284-91	1.8	41	
346	Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes. <i>Transplantation</i> , 1999 , 67, 1418-25	1.8	41	
345	Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. <i>Kidney International</i> , 2016 , 90, 696-704	9.9	40	
344	Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. <i>American Journal of Medicine</i> , 2013 , 126, 501-8	2.4	40	
343	A study of renal outcomes in African American living kidney donors. <i>Transplantation</i> , 2009 , 88, 1371-6	1.8	40	
342	Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. <i>American Journal of Hypertension</i> , 2007 , 20, 807-15	2.3	40	
341	Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. <i>Transplantation</i> , 2013 , 95, 128-36	1.8	39	
340	Polyomavirus reactivation in native kidneys of pancreas alone allograft recipients. <i>Transplantation</i> , 2003 , 75, 1186-90	1.8	39	
339	Pancreas transplantation for diabetes mellitus. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 444-50	7.4	39	
338	Acute kidney injury and cardiovascular outcomes in acute severe hypertension. <i>Circulation</i> , 2010 , 121, 2183-91	16.7	38	
337	Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2612-9	6.9	38	
336	Pretransplant serum C-reactive protein and the risk of chronic allograft nephropathy in renal transplant recipients: a pilot case-control study. <i>American Journal of Kidney Diseases</i> , 2002 , 39, 1096-10	1 ^{7.4}	37	
335	Abnormalities of Potassium in Heart[Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2836-2850	15.1	36	
334	Anemia after kidney transplantation; its prevalence, risk factors, and independent association with graft and patient survival: a time-varying analysis. <i>Transplantation</i> , 2012 , 93, 923-8	1.8	36	
333	Nocturnal reduction of blood pressure and the antihypertensive response to a diuretic or angiotensin converting enzyme inhibitor in obese hypertensive patients. TROPHY Study Group. <i>American Journal of Hypertension</i> , 1998 , 11, 914-20	2.3	36	
332	Histological grading of chronic pancreas allograft rejection/graft sclerosis. <i>American Journal of Transplantation</i> , 2003 , 3, 599-605	8.7	36	

331	The Association of Sleep Duration and Quality with CKD Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 3708-3715	12.7	35
330	Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. <i>American Journal of Kidney Diseases</i> , 2018 , 72, 873-884	7.4	35
329	Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients: Concepts and Controversies. <i>Transplantation</i> , 2017 , 101, 166-181	1.8	34
328	Cigarette smoking, kidney function, and mortality after live donor kidney transplant. <i>American Journal of Kidney Diseases</i> , 2010 , 55, 907-15	7.4	34
327	Therapeutic challenges in the obese diabetic patient with hypertension. <i>American Journal of Medicine</i> , 1996 , 101, 33S-46S	2.4	34
326	First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 182-	-8 .9	34
325	Mycophenolate mofetil reduces the risk of acute rejection less in African-American than in Caucasian kidney recipients. <i>Transplantation</i> , 1998 , 65, 242-8	1.8	34
324	The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. <i>Clinical Transplantation</i> , 2009 , 23, 930-7	3.8	33
323	Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 919-25	4.3	33
322	Radix Tripterygium wilfordiia Chinese herbal medicine with potent immunosuppressive properties. <i>Transplantation</i> , 1990 , 50, 82-6	1.8	33
321	Characterization and implications of the initial estimated glomerular filtration rate @ip@pon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021 , 99, 750-762	9.9	33
320	Acute kidney injury following cardiac surgery: role of perioperative blood pressure control. <i>American Journal of Nephrology</i> , 2011 , 33, 438-52	4.6	32
319	Salt and blood pressure responses to calcium antagonism in hypertensive patients. <i>Hypertension</i> , 1997 , 30, 422-7	8.5	32
318	Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 337-346	7.4	31
317	Effect of Patiromer on Urinary Ion Excretion in Healthy Adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016 , 11, 1769-1776	6.9	31
316	Hemodynamic correlates of proteinuria in chronic kidney disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011 , 6, 2403-10	6.9	31
315	Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study. <i>Journal of Hypertension</i> , 2009 , 27, 886-93	1.9	31
314	Coxibsbeyond the GI tract: renal and cardiovascular issues. <i>Journal of Pain and Symptom Management</i> , 2003 , 25, S41-9	4.8	31

(2010-2005)

313	A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. <i>Hypertension</i> , 2005 , 46, 508-13	8.5	31
312	The metabolic syndrome: a call to action. <i>Coronary Artery Disease</i> , 2006 , 17, 77-80	1.4	30
311	Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. <i>ESC Heart Failure</i> , 2018 , 5, 592-602	3.7	30
310	Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. <i>American Journal of Medicine</i> , 2018 , 131, 555-564.e3	2.4	29
309	Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. Journal of the American College of Cardiology, 2019 , 73, 2691-2700	15.1	28
308	Diltiazem: ten years of clinical experience in the treatment of hypertension. <i>Journal of Clinical Pharmacology</i> , 1995 , 35, 220-32	2.9	28
307	A dose-response trial of once-daily diltiazem. American Heart Journal, 1992, 123, 1022-6	4.9	28
306	Incidence of cytomegalovirus disease in cyclosporine-treated renal transplant recipients based on donor/recipient pretransplant immunity. <i>Transplantation</i> , 1987 , 43, 187-93	1.8	28
305	Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2014 , 23, 306-13	3.5	27
304	Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. <i>Current Opinion in Nephrology and Hypertension</i> , 2000 , 9, 403-11	3.5	27
303	Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ transplant recipients: blood pressure control and immunosuppression. <i>American Journal of Medicine</i> , 1991 , 90, 325	5-3:6s	27
302	Long-term Kidney Transplantation Outcomes Network (APOLLO): Design@and@Rationale. <i>Kidney International Reports</i> , 2020 , 5, 278-288	4.1	27
301	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012 , 81, 568-76	9.9	26
300	Effects of isradipine or enalapril on blood pressure in salt-sensitive hypertensives during low and high dietary salt intake. MIST II Trial Investigators. <i>American Journal of Hypertension</i> , 2000 , 13, 1180-8	2.3	26
299	Hypertensive cardiovascular disease in African Americans. Current Hypertension Reports, 1999, 1, 521-8	4.7	26
298	Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 827-836	7·4	25
297	Current concepts in the diagnosis and classification of renal dysfunction in cirrhosis. <i>American Journal of Nephrology</i> , 2013 , 38, 345-54	4.6	25
296	Reasons for discharges against medical advice: a qualitative study. <i>BMJ Quality and Safety</i> , 2010 , 19, 420-4	5.4	25

295	The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007 , 2, 766-85	6.9	25
294	Gender considerations in hypertension pathophysiology and treatment. <i>American Journal of Medicine</i> , 1996 , 101, 10S-21S	2.4	25
293	Impact of age, race, and obesity on hypertensive mechanisms and therapy. <i>American Journal of Medicine</i> , 1991 , 90, 3S-14S	2.4	25
292	Pharmacologic management of systemic hypertension in blacks. <i>American Journal of Cardiology</i> , 1988 , 61, 46H-52H	3	25
291	Exercise-induced hypertension, endothelial dysfunction, and coronary artery disease in a marathon runner. <i>American Journal of Cardiology</i> , 2007 , 99, 743-4	3	24
290	Albuminuria predicting outcome in diabetes: incidence of microalbuminuria in Asia-Pacific Rim. <i>Kidney International</i> , 2004 , S38-9	9.9	24
289	Should living-unrelated renal transplant recipients receive antibody induction? Results of a clinical experience trial. <i>Transplantation</i> , 2004 , 77, 422-5	1.8	24
288	Patiromer Lowers Serum Potassium When Taken without Food: Comparison to Dosing with Food from an Open-Label, Randomized, Parallel Group Hyperkalemia Study. <i>American Journal of Nephrology</i> , 2017 , 46, 323-332	4.6	23
287	The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 46	1 <i>-</i> 470	23
286	mTOR inhibition: the learning curve in kidney transplantation. <i>Transplant International</i> , 2010 , 23, 447-6	03	23
285	Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetesthe Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>American Heart Journal</i> , 2006 , 152, 867-75	4.9	23
284	Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney. <i>Journal of Diabetes and Its Complications</i> , 2016 , 30, 1162-6	3.2	23
283	Clinical Management of Hyperkalemia. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 744-762	6.4	23
282	Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017 , 22, 434-446	2.6	22
281	Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 1493-1499	6.9	22
280	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. <i>American Journal of Medicine</i> , 2018 , 131, 165-172	2.4	22
279	Effects of high- and low-sodium diets on ambulatory blood pressure in patients with hypertension receiving aliskiren. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010 , 15, 356-63	2.6	22
278	Beta-blockers in the treatment of hypertension: are there clinically relevant differences?. <i>Postgraduate Medicine</i> , 2009 , 121, 90-8	3.7	22

(2010-1996)

277	Histologic findings in islets of whole pancreas allografts: lack of evidence for recurrent cell-mediated diabetes mellitus. <i>Transplantation</i> , 1996 , 62, 1770-2	1.8	22
276	Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 51-61	7.4	21
275	A pilot study to evaluate renal hemodynamics in cirrhosis by simultaneous glomerular filtration rate, renal plasma flow, renal resistive indices and biomarkers measurements. <i>American Journal of Nephrology</i> , 2014 , 39, 543-52	4.6	21
274	ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what@the evidence. <i>Journal of Clinical Hypertension</i> , 2002 , 4, 420-3	2.3	21
273	Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. <i>Metabolism: Clinical and Experimental</i> , 2000 , 49, 1491-5	12.7	21
272	Renal adaptation to the failing heart. <i>Postgraduate Medicine</i> , 1994 , 95, 153-156	3.7	21
271	Safe pancreas transplantation in patients with coronary artery disease. <i>Transplantation</i> , 1997 , 63, 1294-9	91.8	21
270	Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. <i>American Heart Journal</i> , 2020 , 223, 3-11	4.9	20
269	Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2020 , 76, 184-193	7.4	20
268	Human GRK4🛮 42V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition. <i>Hypertension</i> , 2016 , 67, 325-34	8.5	20
267	In the clinic: hypertension. <i>Annals of Internal Medicine</i> , 2014 , 161, ITC1-15; quiz ITC16	8	20
266	Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?. <i>American Journal of Nephrology</i> , 2010 , 31, 469-70	4.6	20
265	The tissue renin-angiotensin-aldosterone system in diabetes mellitus. <i>Current Hypertension Reports</i> , 2004 , 6, 98-105	4.7	20
264	Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. <i>American Journal of Cardiology</i> , 1990 , 66, 14D-20D; discussion 20D-21D	3	20
263	Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation. <i>Transplantation</i> , 1988 , 45, 111-6	1.8	20
262	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 299-307	2.3	20
261	Clinical perspectives on the rationale for potassium supplementation. <i>Postgraduate Medicine</i> , 2015 , 127, 539-48	3.7	19
260	Does blockade of the Renin-Angiotensin-aldosterone system slow progression of all forms of kidney disease?. <i>Current Hypertension Reports</i> , 2010 , 12, 369-77	4.7	19

259	The rationale for combination versus single-entity therapy in hypertension. <i>American Journal of Hypertension</i> , 1998 , 11, 163S-169S	2.3	19
258	Genetic influences on blood pressure response to the cold pressor test: results from the Heredity and Phenotype Intervention Heart Study. <i>Journal of Hypertension</i> , 2008 , 26, 729-36	1.9	19
257	Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 103-12	2.3	19
256	Blood pressure management in the kidney transplant recipient. <i>Advances in Chronic Kidney Disease</i> , 2004 , 11, 172-83	4.7	19
255	The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors. <i>Postgraduate Medicine</i> , 2016 , 128, 290-8	3.7	18
254	Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics. <i>Journal of Hypertension</i> , 2017 , 35 Suppl 1, S57-S63	1.9	18
253	Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. <i>Cardiovascular Therapeutics</i> , 2012 , 30, 342-50	3.3	18
252	Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come?. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 146-52	2.3	18
251	Risk-based classification of hypertension and the role of combination therapy. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 4-12	2.3	18
250	Chronic allograft dysfunction: can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function?. <i>Current Opinion in Organ Transplantation</i> , 2008 , 13, 614-21	2.5	18
249	Usefulness of ARBs and ACE inhibitors in the prevention of vascular dementia in the elderly. <i>The American Journal of Geriatric Cardiology</i> , 2007 , 16, 175-82		18
248	Evidence that the antiproliferative effect of verapamil on afferent and efferent immune responses is independent of calcium channel inhibition. <i>Transplantation</i> , 1992 , 54, 681-5	1.8	18
247	Live Donor Renal Transplant With Simultaneous Bilateral Nephrectomy for Autosomal Dominant Polycystic Kidney Disease Is Feasible and Satisfactory at Long-term Follow-up. <i>Transplantation</i> , 2016 , 100, 407-15	1.8	18
246	Inflammation and Apparent Treatment-Resistant Hypertension in Patients With Chronic Kidney Disease. <i>Hypertension</i> , 2019 , 73, 785-793	8.5	18
245	Adherence to Healthy Dietary Patterns and Risk of CKD Progression and All-Cause Mortality: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. <i>American Journal of Kidney Diseases</i> , 2021 , 77, 235-244	7.4	18
244	Unique metabolomic signature associated with hepatorenal dysfunction and mortality in cirrhosis. <i>Translational Research</i> , 2018 , 195, 25-47	11	18
243	Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1891-1900	2.5	17
242	Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis. Digestive Diseases and Sciences, 2018, 63, 665-675	4	17

241	Epidemiology and Pathophysiology of Glomerular C4d Staining in Native Kidney Biopsies. <i>Kidney International Reports</i> , 2019 , 4, 1555-1567	4.1	17	
240	Determinants of blood pressure response to low-salt intake in a healthy adult population. <i>Journal of Clinical Hypertension</i> , 2011 , 13, 795-800	2.3	17	
239	Hypertension and the kidney: perspectives on the relationship of kidney disease and cardiovascular disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 2045-50	6.9	17	
238	Minimizing the risk of chronic allograft nephropathy. <i>Transplantation</i> , 2009 , 87, S14-8	1.8	17	
237	The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. <i>American Journal of Hypertension</i> , 2005 , 18, 100S-105S	2.3	17	
236	Salt intake and hypertensive renal injury in African-Americans. A therapeutic perspective. <i>American Journal of Hypertension</i> , 1995 , 8, 635-44	2.3	17	
235	Additive inhibition of afferent and efferent immunological responses of human peripheral blood mononuclear cells by verapamil and cyclosporine. <i>Transplantation</i> , 1991 , 51, 851-7	1.8	17	
234	Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. <i>American Journal of Cardiology</i> , 1987 , 60, 36I-41I	3	17	
233	Estimation of Glomerular Filtration Rate in Patients With Cirrhosis by Using New and Conventional Filtration Markers and Dimethylarginines. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 624-632.	e2 ^{6.9}	16	
232	KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline. <i>American Journal of Kidney Diseases</i> , 2019 , 73, 437-458	7.4	16	
231	Thiazide and thiazide-like diuretics: an opportunity to reduce blood pressure in patients with advanced kidney disease. <i>Current Hypertension Reports</i> , 2012 , 14, 416-20	4.7	16	
230	Influence of creatinine versus glomerular filtration rate on non-steroidal anti-inflammatory drug prescriptions in chronic kidney disease. <i>American Journal of Nephrology</i> , 2012 , 36, 19-26	4.6	16	
229	Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 540-8	2.3	16	
228	Early steroid withdrawal in solitary pancreas transplantation results in equivalent graft and patient survival compared with maintenance steroid therapy. <i>Clinical Transplantation</i> , 2007 , 21, 491-7	3.8	16	
227	Does dietary salt increase the risk for progression of kidney disease?. <i>Current Hypertension Reports</i> , 2005 , 7, 385-91	4.7	16	
226	Minimization of indomethacin-induced reduction in renal function by misoprostol. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 729-35	2.9	16	
225	Risk Factors for CKD Progression: Overview of Findings from the CRIC Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 648-659	6.9	16	
224	Expert Panel Recommendations for the Identification and Management of Hyperkalemia and Role of Patiromer in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care & Disease and Heart Failure</i> (1988) 8 July 1988 1989 1989 1989 1989 1989 1989 198	1.9	15	

223	Habitual sleep and kidney function in chronic kidney disease: the Chronic Renal Insufficiency Cohort study. <i>Journal of Sleep Research</i> , 2018 , 27, 281-289	5.8	15
222	Effectiveness of informational decision aids and a live donor financial assistance program on pursuit of live kidney transplants in African American hemodialysis patients. <i>BMC Nephrology</i> , 2018 , 19, 107	2.7	15
221	Impact of Hyperuricemia on Long-term Outcomes of Kidney Transplantation: Analysis of the FAVORIT Study. <i>American Journal of Kidney Diseases</i> , 2017 , 70, 762-769	7.4	15
220	A randomized, double-blind, forced-titration study to compare olmesartan medoxomil versus losartan potassium in patients with stage 1 and 2 hypertension. <i>Postgraduate Medicine</i> , 2011 , 123, 80-7	3.7	15
219	The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 815-25	2.9	15
218	Reevaluation of T cell subset monitoring in cyclosporine-treated renal allograft recipients. <i>Transplantation</i> , 1985 , 40, 620-3	1.8	15
217	Prevalence, Severity, and Impact of Renal Dysfunction in Acute Liver Failure on the US Liver Transplant Waiting List. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 309-16	4	14
216	Defining, Treating, and Understanding Chronic Kidney DiseaseA Complex Disorder. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 514-27	2.3	14
215	A qualitative study to identify reasons for discharges against medical advice in the cardiovascular setting. <i>BMJ Open</i> , 2012 , 2,	3	14
214	Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. <i>Journal of Hypertension</i> , 2010 , 28, 186-93	1.9	14
213	Comparison of dual RAAS blockade and higher-dose RAAS inhibition on nephropathy progression. <i>Postgraduate Medicine</i> , 2008 , 120, 33-42	3.7	14
212	Providing end-organ protection with renin-angiotensin system inhibition: the evidence so far. Journal of Clinical Hypertension, 2006 , 8, 99-105; quiz 106-7	2.3	14
211	Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. <i>Kidney International</i> , 2016 , 90, 861-8	9.9	14
210	Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial. <i>Transplantation</i> , 2017 , 101, 157-165	1.8	13
209	Acute changes in glomerular filtration rate with renin-angiotensin system (RAS) inhibition: clinical implications. <i>Kidney International</i> , 2017 , 91, 529-531	9.9	13
208	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018 , 11, 155-164	2.5	13
207	Treated hypertension and the white coat phenomenon: Office readings are inadequate measures of efficacy. <i>Journal of the American Society of Hypertension</i> , 2013 , 7, 236-43		13
206	Specific management of anemia and hypertension in renal transplant recipients: influence of renin-angiotensin system blockade. <i>American Journal of Nephrology</i> , 2014 , 39, 1-7	4.6	13

205	Management of hypertension in the transplant patient. <i>Journal of the American Society of Hypertension</i> , 2011 , 5, 425-32		13	
204	The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 23-30	2.3	13	
203	Determinants of the renal response to ACE inhibition in patients with congestive heart failure. <i>American Heart Journal</i> , 1992 , 124, 131-6	4.9	13	
202	Prognostic Significance of Ambulatory BP Monitoring in CKD: A Report from the Chronic Renal Insufficiency Cohort (CRIC) Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2609-2	.6 ¹² 1 ⁷	13	
201	A prospective controlled study of metabolic and physiologic effects of kidney donation suggests that donors retain stable kidney function over the first nine years. <i>Kidney International</i> , 2020 , 98, 168-13	7 8 .9	13	
200	Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. <i>Canadian Journal of Diabetes</i> , 2016 , 40, 247-57	2.1	12	
199	Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1409-1417	6.9	12	
198	Acute fall in glomerular filtration rate with renin-angiotensin system inhibition: a biomeasure of therapeutic success?. <i>Kidney International</i> , 2011 , 80, 235-7	9.9	12	
197	The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. <i>Postgraduate Medicine</i> , 2009 , 121, 96-103	3.7	12	
196	Baseline factors associated with congestive heart failure in patients receiving etoricoxib or diclofenac: multivariate analysis of the MEDAL program. <i>European Journal of Heart Failure</i> , 2009 , 11, 542-50	12.3	12	
195	Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD. <i>Clinical Cardiology</i> , 1997 , 20, 562-8	3.3	12	
194	The balance of angiotensin II and nitric oxide in kidney diseases. <i>Current Opinion in Nephrology and Hypertension</i> , 2008 , 17, 51-6	3.5	12	
193	Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. <i>Future Cardiology</i> , 2007 , 3, 519-24	1.3	12	
192	Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. <i>Mineral and Electrolyte Metabolism</i> , 1998 , 24, 438-45		12	
191	Late intervention with the small molecule BB3 mitigates postischemic kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, F352-61	4.3	12	
190	Central Blood Pressure and Cardiovascular Outcomes in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018 , 13, 585-595	6.9	11	
189	Treatment-resistant hypertension in the transplant recipient. Seminars in Nephrology, 2014, 34, 560-70	4.8	11	
188	Have we fallen off target with concerns surrounding dual RAAS blockade?. <i>Kidney International</i> , 2010 , 78, 539-45	9.9	11	

187	Renal allograft biopsy and conversion of cyclosporine to azathioprine. <i>Transplantation</i> , 1989 , 47, 223-9	1.8	11
186	Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal[function?. <i>Clinical Nephrology</i> , 2018 , 89, 314-329	2.1	11
185	Systematic integrated analysis of genetic and epigenetic variation in diabetic kidney disease. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29013-29024	11.5	11
184	Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2019 , 74, 771-781	7.4	10
183	Hypervolemia and blood pressure: powerful indicators of increased mortality among hemodialysis patients. <i>Hypertension</i> , 2010 , 56, 341-3	8.5	10
182	Pharmacological strategies for kidney function preservation: are there differences by ethnicity?. <i>Advances in Chronic Kidney Disease</i> , 2004 , 11, 24-40		10
181	Progressive renal and cardiovascular disease: optimal treatment strategies. <i>Kidney International</i> , 2002 , 62, 1482-92	9.9	10
180	Dietary salt, blood pressure, and microalbuminuria. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 23-6	2.3	10
179	Hypertensive nephropathy: is a more physiologic approach to blood pressure control an important concern for the preservation of renal function?. <i>American Journal of Medicine</i> , 1992 , 93, 27S-37S	2.4	10
178	Calcium channel blockers inhibit cellular uptake of thymidine, uridine and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation. <i>Immunopharmacology</i> , 1993 , 25, 75-82		10
177	Current and future treatment options for managing hyperkalemia. <i>Kidney International Supplements</i> , 2016 , 6, 29-34	6.3	9
176	Readmissions after unauthorized discharges in the cardiovascular setting. <i>Medical Care</i> , 2011 , 49, 215-24	43.1	9
175	The role of angiotensin receptor blockers in diabetic nephropathy. <i>Postgraduate Medicine</i> , 2011 , 123, 109-21	3.7	9
174	The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications. <i>Postgraduate Medicine</i> , 2012 , 124, 40-52	3.7	9
173	Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 1429-34	12.7	9
172	Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.	3.5	9
171	Hypertension in diabetic patients: an update of interventional studies to preserve renal function. Journal of Clinical Pharmacology, 1995 , 35, 73-80	2.9	9
170	Donor-derived Cell-free DNA in Infections in Kidney Transplant Recipients: Case Series. <i>Transplantation Direct</i> , 2020 , 6, e568	2.3	9

169	Recognizing the link between chronic kidney disease and cardiovascular disease. <i>American Journal of Managed Care</i> , 2011 , 17 Suppl 15, S396-402	2.1	9
168	Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2019 , 8, e011013	6	8
167	Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure. <i>Journal of Managed Care & Decialty Pharmacy</i> , 2017 , 23, S2-S9	1.9	8
166	Eosinophilia as an early indicator of pancreatic allograft rejection. Clinical Transplantation, 2012, 26, 238	3-48	8
165	Role of dietary therapies in the prevention and treatment of hypertension. <i>Nature Reviews Nephrology</i> , 2012 , 8, 413-22	14.9	8
164	Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study. <i>Journal of Clinical Lipidology</i> , 2010 , 4, 435-43	4.9	8
163	Prescribing trends and drug budget impact of the ARBs in the UK. Value in Health, 2009, 12, 302-8	3.3	8
162	Urinary sodium is a potent correlate of proteinuria: lessons from the chronic renal insufficiency cohort study. <i>American Journal of Nephrology</i> , 2012 , 36, 397-404	4.6	8
161	A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach. <i>Transplant International</i> , 2008 , 21, 908-14	3	8
160	The beta blockers: are they as protective in hypertension as in other cardiovascular conditions?. <i>Journal of Clinical Hypertension</i> , 2001 , 3, 236-43	2.3	8
159	Telmisartan in incipient and overt diabetic renal disease. <i>Journal of Nephrology</i> , 2011 , 24, 263-73	4.8	8
158	Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 1396-1402	4.5	8
157	A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease. <i>American Journal of Nephrology</i> , 2017 , 46, 364-370	4.6	7
156	Effect of dietary sodium on insulin sensitivity in older, obese, sedentary hypertensives. <i>American Journal of Hypertension</i> , 1997 , 10, 964-70	2.3	7
155	Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. <i>American Journal of Cardiology</i> , 1998 , 81, 1363	3 ³ 5	7
154	Calcium channel blockers: their pharmacologic and therapeutic role in hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2007 , 7 Suppl 1, 5-15	4	7
153	Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering?. <i>Current Opinion in Nephrology and Hypertension</i> , 2007 , 16, 416-21	3.5	7
152	Reduction in microalbuminuria: a biomeasure of therapeutic success?. <i>Hypertension</i> , 2005 , 45, 181-2	8.5	7

151	Physiologic and hemodynamic considerations in blood pressure control while maintaining organ perfusion. <i>American Journal of Cardiology</i> , 1988 , 61, 60H-66H	3	7
150	Late pancreas allograft rejection. Preliminary experience with factors predisposing to rejection. <i>Transplantation</i> , 1996 , 62, 539-43	1.8	7
149	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1503-1519	6.4	7
148	Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial. <i>Clinical Cardiology</i> , 2017 , 40, 633-640	3.3	6
147	Blood pressure response with fixed-dose combination therapy: comparing hydrochlorothiazide with amlodipine through individual-level meta-analysis. <i>Journal of Hypertension</i> , 2013 , 31, 1692-701	1.9	6
146	Renin angiotensin system inhibition in the older person: a review. <i>Clinics in Geriatric Medicine</i> , 2009 , 25, 245-57	3.8	6
145	Is activated vitamin D supplementation renoprotective?. <i>Hypertension</i> , 2008 , 52, 211-2	8.5	6
144	COX-2 inhibitors and cardiovascular risk. <i>Sub-Cellular Biochemistry</i> , 2007 , 42, 159-74	5.5	6
143	Optimal strategies for modeling the reciprocal of creatinine versus time in renal transplant recipients and patients with native chronic renal disease. <i>American Journal of Kidney Diseases</i> , 2002 , 39, 753-61	7.4	6
142	Current perspective on the cardiovascular effects of coxibs. <i>Cleveland Clinic Journal of Medicine</i> , 2002 , 69 Suppl 1, SI47-52	2.8	6
141	Adverse Health Outcomes Associated With Refractory and Treatment-Resistant Hypertension in the Chronic Renal Insufficiency Cohort. <i>Hypertension</i> , 2021 , 77, 72-81	8.5	6
140	Kidney function assessment and endpoint ascertainment in clinical trials European Heart Journal, 2021 ,	9.5	6
139	CCR2 inhibition: a panacea for diabetic kidney disease?. <i>Lancet Diabetes and Endocrinology,the</i> , 2015 , 3, 666-7	18.1	5
138	The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient. <i>Current Cardiology Reports</i> , 2015 , 17, 95	4.2	5
137	Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results. <i>American Journal of</i>	4.6	5
136	Nephrology, 2020, 51, 276-288 Safety events in kidney transplant recipients: results from the folic Acid for vascular outcome reduction in transplant trial. <i>Transplantation</i> , 2015, 99, 1003-8	1.8	5
135	Usability of mobile technology to screen for drug-drug interactions in kidney transplant patients. <i>American Journal of Nephrology</i> , 2014 , 40, 97-104	4.6	5
134	Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? Con position. <i>Journal of the American Society of Hypertension</i> , 2012 , 6, 443-7		5

(1990-2010)

133	Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS). <i>Journal of Clinical Lipidology</i> , 2010 , 4, 165-72	4.9	5
132	Renal function and cardiovascular response to mental stress. <i>American Journal of Nephrology</i> , 2008 , 28, 304-10	4.6	5
131	Essential hypertension in blacks: is it a metabolic disorder?. <i>American Journal of Kidney Diseases</i> , 1993 , 21, 58-67	7.4	5
130	Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	5
129	Blood Pressure and Living Kidney Donors: A Clinical Perspective. <i>Transplantation Direct</i> , 2019 , 5, e488	2.3	5
128	The Effects of Candesartan Cilexetil in Isolated Systolic Hypertension: A Clinical Experience Trial. <i>Journal of Clinical Hypertension</i> , 2000 , 2, 181-186	2.3	5
127	Anemia and Incident End-Stage Kidney Disease. <i>Kidney360</i> , 2020 , 1, 623-630	1.8	4
126	Hyperkalemia in the Hypertensive Patient. Current Cardiology Reports, 2018, 20, 12	4.2	4
125	Salt, hypertension, and proteinuria in diabetic nephropathy. <i>Lancet Diabetes and Endocrinology,the</i> , 2014 , 2, 351-2	18.1	4
124	Patiromer Reduces Serum K+ in Hyperkalemic Patients with HF and CKD on RAAS Inhibitors: Results from OPAL-HK and AMETHYST-DN. <i>Journal of Cardiac Failure</i> , 2015 , 21, S107-S108	3.3	4
123	Efficacy of amlodipine/olmesartan medoxomil hydrochlorothiazide in patients aged 16 5 or Postgraduate Medicine, 2013 , 125, 124-34	3.7	4
122	Relative plasma volume monitoring and blood pressure control: an overlooked opportunity to achieve dry weight in the hemodialysis patient. <i>Hypertension</i> , 2010 , 55, 226-7	8.5	4
121	Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. <i>Kidney International</i> , 2011 , 80, 1016-7	9.9	4
120	Optimal blood pressure for a patient with type 2 diabetes mellitus: insight from the ACCORD study. <i>Current Hypertension Reports</i> , 2010 , 12, 313-5	4.7	4
119	Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction. <i>Journal of Clinical Hypertension</i> , 2004 , 6, 315-23; quiz 324-5	2.3	4
118	Supplementation of Immunosuppressive Regimens with Calcium Channel Blockers. <i>BioDrugs</i> , 1994 , 2, 458-467		4
117	VALUE OF IN VITRO CD4+ T HELPER CELL FUNCTION TEST FOR PREDICTING LONG-TERM LOSS OF HUMAN RENAL ALLOGRAFTS. <i>Transplantation</i> , 1994 , 57, 480-482	1.8	4
116	Evaluation of the clinical pharmacology of nilvadipine in patients with mild to moderate essential hypertension. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 425-37	2.9	4

115	Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. <i>European Journal of Heart Failure</i> , 2021 , 24, 230	12.3	4
114	Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program. <i>Drugs - Real World Outcomes</i> , 2021 , 8, 315-323	2.2	4
113	Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. <i>Transplantation</i> , 2021 , 105, 443-450	1.8	4
112	Predicting, preventing, and managing cardiovascular and chronic kidney disease progression in people with type 2 diabetes: How to improve on traditional strategies. <i>Journal of Diabetes</i> , 2019 , 11, 619-622	3.8	3
111	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018 , 11, 1-7	2.5	3
110	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. <i>International Journal of Nephrology and Renovascular Disease</i> , 2017 , 10, 233-242	2.5	3
109	Hypertension and kidney disease. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 855-7; quiz 858-9		3
108	Optimal dietary strategies for reducing incident hypertension. <i>Hypertension</i> , 2009 , 54, 698-9	8.5	3
107	What is left ventricular hypertrophy and is there a reason to regress left ventricular hypertrophy?. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 407-10	2.3	3
106	Newer combination therapies in the management of hypertension: an update. <i>Journal of Clinical Hypertension</i> , 2008 , 10, 398-405	2.3	3
105	Clinical trials report. Adverse prognostic significance of new diabetes in treated hypertensive subjects. <i>Current Hypertension Reports</i> , 2004 , 6, 365-6	4.7	3
104	Is chronic calcineurin inhibitor toxicity responsible for long-term deterioration of renal function in transplant recipients?. <i>Transplantation Reviews</i> , 2003 , 17, 20-30	3.3	3
103	The inevitability of renal function loss in patients with hypercreatinemia. <i>American Journal of Nephrology</i> , 2001 , 21, 386-9	4.6	3
102	Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. <i>Postgraduate Medicine</i> , 1992 , 91, 77-80, 83-4	3.7	3
101	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review <i>JAMA Cardiology</i> , 2022 ,	16.2	3
100	Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents. <i>American Journal of Nephrology</i> , 2021 , 52, 450-466	4.6	3
99	Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. <i>Postgraduate Medicine</i> , 2019 , 131, 367-375	3.7	2
98	New agents for hyperkalemia. <i>New England Journal of Medicine</i> , 2015 , 372, 1570-1	59.2	2

(2020-2015)

97	Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2015 , 44, 550	2.6	2
96	Metabolomic biomarkers are associated with mortality in patients with cirrhosis caused by primary biliary cholangitis or primary sclerosing cholangitis. <i>Future Science OA</i> , 2019 , 6, FSO441	2.7	2
95	Lower Blood Pressure (BP) with Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM). <i>Canadian Journal of Diabetes</i> , 2013 , 37, S3	2.1	2
94	Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2010 , 19, 437-43	3.5	2
93	How do you define "hypertension" in a patient with type 1 diabetes?. Hypertension, 2007, 49, 13-4	8.5	2
92	Blood pressure salt sensitivity: a biomeasure of kidney disease susceptibility in diabetics?. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 2022-4	4.3	2
91	Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers. <i>Current Hypertension Reports</i> , 2002 , 4, 333-5	4.7	2
90	The role of angiotensin II and TGF-beta on the progression of chronic allograft nephropathy. <i>JRAAS</i> - <i>Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001 , 2, S188-S190	3	2
89	Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?. <i>Current Hypertension Reports</i> , 2000 , 2, 497-9	4.7	2
88	Enzyme-linked immunosorbent assay for serum renal tubular antigen in kidney transplant patients. <i>Transplantation</i> , 1985 , 40, 642-7	1.8	2
87	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases <i>Journal of Diabetes and Its Complications</i> , 2021 , 36, 108101	3.2	2
86	The use of thiazides in chronic kidney disease. Current Hypertension Reviews, 2014, 10, 81-5	2.3	2
85	Effect of Levothyroxine on Kidney Function in Chronic Kidney Disease with Subclinical Hypothyroidism in US Veterans: A Retrospective Observational Cohort Study. <i>Advances in Therapy</i> , 2021 , 38, 1185-1201	4.1	2
84	Recipient outcome after receiving a laparoscopically harvested kidney from a living donor. <i>Transplantation</i> , 2001 , 72, 355-6	1.8	2
83	Causes of Renal Allograft Injury in Recipients With Normal Donor-derived Cell-free DNA. <i>Transplantation Direct</i> , 2021 , 7, e679	2.3	2
82	Defining a minimal clinically meaningful difference in 12-month estimated glomerular filtration rate for clinical trials in deceased donor kidney transplantation. <i>Clinical Transplantation</i> , 2021 , 35, e143	2ફે. ⁸	2
81	Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2019 , 25, 436-447	3.3	2
80	Association of 24-Hour Ambulatory Blood Pressure Patterns with Cognitive Function and Physical Functioning in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 455-464	6.9	2

79	Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 108029	3.2	2
78	How Low Should We Treat Blood Pressure and Why?. Journal of Clinical Hypertension, 1999, 1, 199-208	2.3	2
77	Validation and clinical outcome in assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study <i>Kidney International</i> , 2021 ,	9.9	2
76	Diabetic nephropathy: Nonsteroidal MRA added to RAS blockade reduces albuminuria. <i>Nature Reviews Nephrology</i> , 2015 , 11, 691-2	14.9	1
75	Is there an optimal strategy for pretransplant cardiovascular screening?. <i>Transplantation</i> , 2015 , 99, 656-	-7 1.8	1
74	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. <i>Journal of Hypertension</i> , 2011 , 29, 2031-7	1.9	1
73	Dietary fructose and elevated levels of blood pressure. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 1416-8	12.7	1
72	The death of John Paul Jones and resurrection as © ather of the US NavyO <i>American Journal of Nephrology</i> , 2010 , 31, 90-4	4.6	1
71	Assessing the blood pressure-lowering efficacy of antihypertensive medications: which blood pressures should we use?. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 155-8	2.3	1
70	Gauging adequacy of cardiovascular disease treatment: importance of estimating glomerular filtration rate and time-varying albuminuria. <i>Journal of the American Society of Hypertension</i> , 2009 , 3, 277-85		1
69	The influence of dietary salt on the antiproteinuric effect of calcium channel blockers. <i>American Journal of Kidney Diseases</i> , 1997 , 29, 800-5	7.4	1
68	Treatment of prehypertension: how soon is soon enough? What therapy should be used?. <i>Current Hypertension Reports</i> , 2006 , 8, 393-4	4.7	1
67	Clinical trials report. Chronic kidney disease: blood pressure, treatment goals, and cardiovascular outcomes. <i>Current Hypertension Reports</i> , 2003 , 5, 405-7	4.7	1
66	Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. <i>Postgraduate Medicine</i> , 1992 , 91, 87-91, 94-5	3.7	1
65	Preliminary observations of the acute effects of selective serum thromboxane inhibition and angiotensin converting enzyme inhibition on blood pressure and renal hemodynamics in hypertensive humans. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 1108-16	2.9	1
64	KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD <i>American Journal of Kidney Diseases</i> , 2022 ,	7.4	1
63	Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes. <i>Diabetes Therapy</i> , 2021 , 12, 3167-3186	3.6	1
62	Renal Protection in Chronic Kidney Disease 2005 , 281-294		1

Antihypertensive Drugs 2012, 1824-1878 61 1 Pharmacogenomics of G Protein-Coupled Receptor Signaling and Other Pathways in Essential 60 1.1 Hypertension. Methods in Pharmacology and Toxicology, 2014, 299-312 An evidence-based appraisal of complementary and alternative medicine strategies for the 59 1.9 1 management of hypertension. Journal of Hypertension, 2020, 38, 1412-1419 The Importance of Bringing Transplantation Tolerance to the Clinic. Transplantation, 2021, 105, 935-940_{1.8} 58 Real-World Diagnosis and Treatment of Diabetic Kidney Disease. Advances in Therapy, 2021, 38, 4425-4441 1 57 Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?. European 56 12.3 Journal of Heart Failure, 2016, 18, 216 Association Between APOL1 Genotype and Need for Kidney Replacement Therapy in Patients 1 55 7.4 Without Diabetes: Does Age Matter?. American Journal of Kidney Diseases, 2020, 75, 294-296 Reserpine: A New Consideration of and Old Drug for Refractory Hypertension. American Journal of 2.3 54 Hypertension, **2020**, 33, 708-710 A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Journal of 12.7 1 53 the American Society of Nephrology: JASN, 2021, 32, 469-478 Diabetic nephropathy after kidney transplantation in patients with pretransplantation type II diabetes: A retrospective case series study from a high-volume center in the United States. Clinical 3.8 52 Transplantation, 2018, 32, e13425 Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial. 51 6.7 1 Diabetes, Obesity and Metabolism, 2022, 24, 12-20 Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation.. 1.8 50 Kidney360, **2021**, 2, 1998-2009 The Role of Multiple Drug Therapy for Controlling Hypertension in African Americans. Journal of 49 2.3 1 Clinical Hypertension, 2000, 2, 99-108 Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction. Digestive Diseases and Sciences, 2015, 48 4 0 60, 3491-4 Response to letter regarding article "Rivaroxaban versus warfarin in patients with nonvalvular atrial 47 4.9 O fibrillation and stage IV-V chronic kidney disease". American Heart Journal, 2020, 223, 111-112 46 The Reply. American Journal of Medicine, 2018, 131, e349-e351 2.4 Cyclosporine reduction causes decreasing of angiotensin II and transforming growth factor-beta 45 O expression in chronic allograft nephropathy. Journal of Cardiothoracic-Renal Research, 2006, 1, 81-88 Optimizing target-organ protection in patients with diabetes mellitus: angiotensin-converting 4.7 enzyme inhibitors or angiotensin receptor blockers?. Current Hypertension Reports, 2003, 5, 192-8

43	Emergency Department/Urgent Care as Usual Source of Care and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort Study <i>Kidney Medicine</i> , 2022 , 4, 100424	2.8	0
42	Prediction of Incident Heart Failure in CKD: The CRIC Study <i>Kidney International Reports</i> , 2022 , 7, 708-7	119 1	O
41	Hyperkalemia management in the emergency department: An expert panel consensus. <i>Journal of the American College of Emergency Physicians Open</i> , 2021 , 2, e12572	1.6	O
40	Apparent Treatment-Resistant Hypertension Assessed by Office and Ambulatory Blood Pressure in Chronic Kidney Disease-A Report from the Chronic Renal Insufficiency Cohort Study. <i>Kidney360</i> , 2020 , 1, 810-818	1.8	O
39	Hematologic and Infectious Complications of Chronic Kidney Disease 2020 , 477-502		O
38	Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm <i>Kidney360</i> , 2020 , 1, 1148-1156	1.8	O
37	Patients and sudden death in dialysis: the HeartLink focus groups pilot study. <i>BMC Nephrology</i> , 2021 , 22, 199	2.7	0
36	The Author Replies. <i>Kidney International</i> , 2017 , 92, 1016-1017	9.9	
35	Inhibition of the ReninAngiotensin System: How Far Have We Come? 2017 , 77-95		
34	The authors reply. Kidney International, 2015, 87, 863-4	9.9	
34	The authors reply. <i>Kidney International</i> , 2015 , 87, 863-4 Hematologic Complications of Chronic Kidney Disease 2015 , 277-284	9.9	
		9.9	
33	Hematologic Complications of Chronic Kidney Disease 2015 , 277-284		
33	Hematologic Complications of Chronic Kidney Disease 2015 , 277-284 The authors reply. <i>Kidney International</i> , 2020 , 97, 213-214 OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN	9.9	
33 32 31	Hematologic Complications of Chronic Kidney Disease 2015, 277-284 The authors reply. <i>Kidney International</i> , 2020, 97, 213-214 OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. <i>Journal of Hypertension</i> , 2016, 34, e229 Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. <i>American Journal</i>	9.9	
33 32 31 30	Hematologic Complications of Chronic Kidney Disease 2015, 277-284 The authors reply. <i>Kidney International</i> , 2020, 97, 213-214 OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. <i>Journal of Hypertension</i> , 2016, 34, e229 Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. <i>American Journal of Nephrology</i> , 2016, 44, 169 Noteworthy observations in hypertension from 2015. <i>Current Opinion in Nephrology and</i>	9.9 1.9 4.6	
33 32 31 30 29	Hematologic Complications of Chronic Kidney Disease 2015, 277-284 The authors reply. <i>Kidney International</i> , 2020, 97, 213-214 OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD. <i>Journal of Hypertension</i> , 2016, 34, e229 Rivaroxaban in Chronic Hemodialysis Patients: Clarification of an Editorial Error. <i>American Journal of Nephrology</i> , 2016, 44, 169 Noteworthy observations in hypertension from 2015. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 1-2	9.9 1.9 4.6	

(2011-2013)

25	Benefits Improvement and Protection Act@ impact on transplantation rates among elderly MEDICARE beneficiaries with end-stage renal disease. <i>Transplantation</i> , 2013 , 95, 463-9	1.8
24	The Obesity Paradox: Impact of Obesity on the Prevalence and Prognosis of Cardiovascular Diseases. <i>Postgraduate Medicine</i> , 2009 , 121, 164-165	3.7
23	The Author Replies:. <i>Kidney International</i> , 2011 , 79, 1379-1380	9.9
22	A 72-year-old woman with several months of weight loss and generalized weakness. <i>American Journal of the Medical Sciences</i> , 2012 , 344, 142-5	2.2
21	Direct renin inhibitors: where will they fit in for antihypertensive treatment?. <i>Current Hypertension Reports</i> , 2007 , 9, 389-91	4.7
20	Are we "ONTARGET" yet with regard to optimal antihypertensive regimens?. <i>Current Hypertension Reports</i> , 2008 , 10, 385-6	4.7
19	Healthy diet and blood pressure. Journal of Clinical Hypertension, 2004, 6, 381-2	2.3
18	Use of angiotensin II receptor blockers alone and in combination with other drugs: a large clinical experience trial. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2001 , 2, S217-S222	3
17	Wednesday, may 17, broadway ballroom north, 3:00 pm to 5:00 pm. new blood pressure goals: Reality or fantasy-the importance of combination therapy: Achieving low blood pressure for the kidney: Is there really a problem?. <i>American Journal of Hypertension</i> , 2000 , 13, S329	2.3
16	Hypertension in patients with type 2 diabetes. <i>Hospital Practice (1995)</i> , 2001 , 36, 41-2, 47-8, 51-4; discussion 54	2.2
15	Appropriate use of calcium antagonists in hypertension. <i>Hospital Practice (1995)</i> , 2001 , 36, 47-8, 53-5	2.2
14	Hypertension: goal systolic and diastolic blood pressure. Current Hypertension Reports, 1999, 1, 411-3	4.7
13	Indicators and treatment of hypertensive heart disease. <i>Hospital Practice (1995)</i> , 1999 , 34, 93-4, 99-100, 103-4 passim	2.2
12	Clinical commentary: how to choose blood pressure goals and treatment: influence of estimated glomerular filtration rate and albuminuria. <i>Transactions of the American Clinical and Climatological Association</i> , 2008 , 119, 53-61; discussion 61-3	0.9
11	Antihypertensive therapy: Progression of Renal Injury 2003 , 209-240	
10	Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events 2005 , 543-556	
9	132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects. <i>Diabetes</i> , 2020 , 69, 132-LB	0.9
8	Chronic Kidney Disease in the Primary Care Setting: Importance for Estimating Cardiovascular Disease Risk and Use of Appropriate Therapies 2011 , 165-183	

Dual Blockade of the Renin Angiotensin Aldosterone System: Benefits Versus Adverse Outcomes **2012**, 453-465

6	BLOOD PRESSURE EFFECTS OVER TIME OF BIPOLAR RADIOFREQUENCY RENAL DENERVATION IN UNTREATED HYPERTENSION. <i>Journal of Hypertension</i> , 2021 , 39, e10	1.9
5	Early Kidney Allograft Dysfunction (Threatened Allograft): Comparative Effectiveness of Continuing Versus Discontinuation of Tacrolimus and Use of Sirolimus to Prevent Graft Failure: A Retrospective Patient-Centered Outcome Study. <i>Transplantation Direct</i> , 2016 , 2, e98	2.3
4	OS 19-03 TREATMENT WITH PATIROMER RESULTED IN DECREASES IN ALDOSTERONE IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERKALEMIA ON RAAS INHIBITORS. <i>Journal of Hypertension</i> , 2016 , 34, e228-e229	1.9
3	Chronic Kidney Disease in the Primary Care Setting: Cardiovascular Disease Risk and Management. <i>Contemporary Cardiology</i> , 2019 , 179-216	0.1
2	Hypertension in Elderly African-Americans. <i>The American Journal of Geriatric Cardiology</i> , 1997 , 6, 13-20	
1	Recognition and Management of a Less Common Cause of Chronic Kidney Disease: Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Family Practice</i> , 2020 , 69, S57-S62	O.2